Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Blend · Conestoga

Conestoga Discovery Fund Institutional Class (CMIRX)

Ticker CMIRX · Since 2018-11-30 · · Holdings as of Jun 30, 2026

Expense ratio
1.25%$125/yr per $10k
5-yr return
−0.6%annualized
1-yr return
+16.6%as of Dec 2025
Net assets
$5.7Mall share classes
Holdings
29

Bottom line

Is CMIRX a good fund? The bottom line

CMIRX is the Institutional Class share class of Conestoga Discovery Fund, an actively managed large blend mutual fund from Conestoga.

Annual fees run 1.25% — about $125 a year on every $10,000 invested, more expensive than 76% of large blend funds we track.

It returned +16.6% over one year, −0.6% a year over five years (as of Dec 31, 2025, per its prospectus).

With $5.7 million in net assets and 29 holdings, its largest position is Twist Bioscience Corp (5.6%) and the top 10 make up 46.7% of the portfolio.

What to watch

  • Expensive for its category (1.25%)
  • 5-year return in the bottom quarter of its category
  • Small fund ($5.7 million) — small funds are likelier to close

Updated Nov 19, 2026

What CMIRX invests in

The Fund seeks to provide long-term growth of capital.

Under normal market circumstances, the Fund invests at least 80% of its net assets in equity securities of micro-capitalization companies. Equity securities include common and preferred stocks, both domestic and foreign, convertible securities, rights, warrants and American depositary receipts (ADRs). While there is no limit on investing in foreign securities, the Fund does not expect investment in foreign securities to exceed 20% of the Funds total assets. The Adviser considers micro market capitalization (micro-cap) companies for this purpose to be those companies that, at the time of initial purchase (including the existing portfolio), have market capitalizations generally within the range of companies included in the Russell Micro Cap Growth Index. The Fund will not change this policy unless it notifies shareholders at least 60 days in advance. This policy does not require the Fund…

From the fund's prospectus (filed Feb 3, 2026).

CMIRX performance

Average annual total returns
1 yr5 yr10 yr
CMIRX+16.6%−0.6%—
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full CMIRX performance history →

What CMIRX costs

On a $10,000 investment, CMIRX's 1.25% expense ratio costs about $125 a year. The prospectus estimates $6,151 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full CMIRX fee table →

CMIRX top 10 holdings

#Holding% of fund
1Twist Bioscience Corp5.59%
2Mama's Creations Inc5.36%
3Vericel Corp5.04%
4Digi International Inc5.02%
5Transcat Inc4.47%
6Electrovaya Inc4.46%
7Graham Corp4.28%
8Biolife Solutions Inc4.23%
9Palomar Holdings Inc4.20%
10Cryoport Inc4.06%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 46.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to CMIRX

More funds like CMIRX →

CMIRX FAQ

What is the expense ratio of CMIRX?
CMIRX's expense ratio is 1.25%, which works out to about $125 a year for every $10,000 invested. The prospectus estimates total costs of $6,151 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is CMIRX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.25%); 5-year return in the bottom quarter of its category; small fund ($5.7 million) — small funds are likelier to close. This is general information, not personalized advice.
What does CMIRX hold?
CMIRX's largest holdings are Twist Bioscience Corp (5.6%), Mama's Creations Inc (5.4%), Vericel Corp (5.0%), Digi International Inc (5.0%), Transcat Inc (4.5%). It holds 29 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is CMIRX's 5-year return?
CMIRX returned −0.6% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Who manages CMIRX?
CMIRX is offered by Conestoga through Conestoga Funds.